Da Silva D M, Velders M P, Rudolf M P, Schiller J T, Kast W M
Cardinal Bemardin Cancer Center & Department of Microbiology & Immunology, Loyola University, Chicago, 2160 S First Avenue, Maywood, IL 60153, USA.
Curr Opin Mol Ther. 1999 Feb;1(1):82-8.
Papillomavirus virus-like particles (VLPs) are empty, non-replicative, non-infectious particles that retain conformationally correct epitopes for the generation of antibody responses to the viral capsid proteins. Chimeric human papillomavirus (HPV) virus-like particles incorporating non-structural virus proteins offer an exciting approach for combined prophylactic and therapeutic vaccines against HPV-induced lesions. Both HPV VLPs and chimeric VLPs can induce potent humoral and cellular immune responses when injected into mice, leading to the generation of virus-neutralizing antibodies, priming of CD8+ T-cells and activation of cytotoxic T-cell effector functions. This review summarizes recent advances in the production of chimeric VLPs, the immune response elicited by VLPs and chimeric VLPs, and their ability to generate strong protective and therapeutic antitumor immune responses.
乳头瘤病毒样颗粒（VLPs）是空心的、无复制能力且无感染性的颗粒，其保留了构象正确的表位，可用于产生针对病毒衣壳蛋白的抗体反应。包含非结构病毒蛋白的嵌合人乳头瘤病毒（HPV）病毒样颗粒为开发针对HPV诱导病变的联合预防性和治疗性疫苗提供了一种令人兴奋的方法。当将HPV VLPs和嵌合VLPs注射到小鼠体内时，二者均可诱导强大的体液免疫和细胞免疫反应，从而产生病毒中和抗体、启动CD8 + T细胞并激活细胞毒性T细胞效应功能。本综述总结了嵌合VLPs生产方面的最新进展、VLPs和嵌合VLPs引发的免疫反应，以及它们产生强大的保护性和治疗性抗肿瘤免疫反应的能力。
